Dose: 6.25 mg/day
Single Dose: 6.2 (6.25)
Frequency: As recommended.
Route: PO
Instructions: In patients with hepatic impairment the maximum daily dose should not exceed 12.5 mg over a 24-hour period.

. It is of Synthetic origin. . The Molecular Weight of Almotriptan is 469.56.

Almotriptan is contraindicated in conditions like Peripheral vascular disease,Cerebrovascular accident,Uncontrolled hypertension,Severe hypertension associated with renal disease.

The symptomatic adverse reactions produced by Almotriptan are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Drowsiness, Fatigue, Diarrhea, Dry mouth, Dysuria, Dyspepsia, Transient increase in blood pressure, Flushing, Nausea and vomiting, Tingling, Sensation of warmth, Heaviness.

Almotriptan is primarily indicated in conditions like Migraine.

Almotriptan is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementErgotamine (Tartrate)VORICONAZOLEVoriconazole may increase the serum concentration of almotriptan by decreasing its metabolism.dose adjestment requiredVortioxetine increase toxicity of vortioxetinemonitor closely or use alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

tabs Store at room temperature, . Protect from Moisture and Heat.

5HT1 agonists (e.g Almotriptan) should be used with caution in conditions which predispose to coronary artery disease (pre-existing cardiac disease), pregnancy and breast-feeding. 5HT1 agonist s are recommended as monotherapy and should not be taken concurrently with other acute migraine therapies. Little information is available on the use of these drugs in the elderly (over 65 year). Caution is also required in mild or moderate hepatic impairment; severe renal impairment; sensitivity to sulphonamides; not to be taken until 24 hours after stopping ergotamine-type prepration (ergotamine-type prepration not to be taken until 6 hours after Almotriptan)